Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open Label, Multicenter, Single Arm Study to Assess the Safety, Tolerability and Immunogenicity of VLA2001 in Volunteers Aged ≥ 56 Years.

NCT04956224 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT04956224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04956224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open Label, Multicenter, Single Arm Study to Assess the Safety, Tolerability and Immunogenicity of VLA2001 in Volunteers Aged ≥ 56 Years.
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Completed
Start date
August 9, 2021
Completion date
November 18, 2022
Enrollment
306 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 virus infection